C. L. Bohas

Gemcitabine and oxaliplatin combination chemotherapy for metastatic well‐differentiated neuroendocrine carcinomas

V. Hervieu, J. Scoazec, J. Chayvialle, 2009, Cancer.

1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

A. Lièvre, C. Lepage, J. Scoazec, 2020 .

Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.

Y. Bang, E. Raymond, A. Vinik, 2016 .

Everolimus for advanced pancreatic neuroendocrine tumors.

E. D. de Vries, E. Van Cutsem, James C Yao, 2011, The New England journal of medicine.

LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

I. Sobhani, A. Lièvre, C. Lepage, 2022, Annals of Oncology.

Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSé Program.

C. Tournigand, G. Ferretti, G. Vassal, 2015 .

Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study.

P. Ruszniewski, J. Valle, M. Caplin, 2014 .